These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23811701)

  • 41. Third-generation salvage cryotherapy for radiorecurrent prostate cancer: a centre's experience.
    Philippou P; Yap T; Chinegwundoh F
    Urol Int; 2012; 88(2):137-44. PubMed ID: 22285952
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review.
    Duijzentkunst DA; Peters M; van der Voort van Zyp JR; Moerland MA; van Vulpen M
    World J Urol; 2016 Nov; 34(11):1521-1531. PubMed ID: 27012712
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Understanding participation in a trial comparing cryotherapy and radiation treatment.
    Eng M; Taylor L; Verhoef M; Ernst S; Donnelly B
    Can J Urol; 2005 Apr; 12(2):2607-13. PubMed ID: 15877944
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thermal-based treatment options for localized prostate cancer.
    Koch MO; Gardner TA
    Curr Treat Options Oncol; 2005 Sep; 6(5):379-87. PubMed ID: 16107241
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostate specific antigen only progression of prostate cancer.
    Moul JW
    J Urol; 2000 Jun; 163(6):1632-42. PubMed ID: 10799151
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cryotherapy for prostate cancer.
    Bermejo CE; Pisters LL
    Expert Rev Anticancer Ther; 2003 Jun; 3(3):393-401. PubMed ID: 12820781
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer.
    Muto S; Yoshii T; Saito K; Kamiyama Y; Ide H; Horie S
    Jpn J Clin Oncol; 2008 Mar; 38(3):192-9. PubMed ID: 18281309
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Achieving the 'bifecta' using salvage cryotherapy for locally recurrent prostate cancer: analysis of the Cryo On-Line Data (COLD) registry data.
    Spiess PE; Given RW; Jones JS
    BJU Int; 2012 Jul; 110(2):217-20. PubMed ID: 21992443
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Prostate cancer treatments in Belgium].
    Kaitouni MI; Roumeguère T
    Rev Med Brux; 2009 Sep; 30(4):270-8. PubMed ID: 19899373
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quality of life outcomes following treatment for localized prostate cancer: is there a clear winner?
    Parker WR; Montgomery JS; Wood DP
    Curr Opin Urol; 2009 May; 19(3):303-8. PubMed ID: 19300266
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Focal therapy for prostate cancer. Alternative treatment.
    Gómez-Veiga F; Martínez-Breijo S; Solsona-Narbón E; Hernández C; Ciudin A; Ribal MJ; Dickinson L; Moore C; Ahmed H; Rodríguez Antolín A; Breda A; Gaya J; Portela-Pereira P; Emberton M
    Actas Urol Esp; 2014 Sep; 38(7):465-75. PubMed ID: 24612733
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nerve-sparing focal cryoablation of prostate cancer.
    Polascik TJ; Mayes JM; Mouraviev V
    Curr Opin Urol; 2009 Mar; 19(2):182-7. PubMed ID: 19188772
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prostate cancer recurrence after Focal Therapy: Treatment options.
    Hamid S; Guillaumier S; Shah T; Arya M; Ahmed HU
    Arch Esp Urol; 2016 Jul; 69(6):375-83. PubMed ID: 27416641
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Active surveillance failure for prostate cancer: does the delay in treatment increase the risk of urinary incontinence?
    Radomski L; Gani J; Trottier G; Finelli A
    Can J Urol; 2012 Jun; 19(3):6287-92. PubMed ID: 22704315
    [TBL] [Abstract][Full Text] [Related]  

  • 56. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
    Barocas DA; Cowan JE; Smith JA; Carroll PR;
    J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cystectomy and Urinary Diversion for the Management of a Devastated Lower Urinary Tract Following Prostatic Cryotherapy and/or Radiotherapy.
    Sack BS; Langenstroer P; Guralnick ML; Jacobsohn KM; O'Connor RC
    WMJ; 2016 Apr; 115(2):70-3. PubMed ID: 27197339
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Focal or subtotal therapy for early stage prostate cancer.
    Jones JS
    Curr Treat Options Oncol; 2007 Jun; 8(3):165-72. PubMed ID: 17701110
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Focal therapy for prostate cancer: recent advances and future directions.
    Wang A; O'Connor LP; Yerram NK; Nandanan N; Ahdoot M; Lebastchi AH; Gurram S; Chalfin H; Pinto PA
    Clin Adv Hematol Oncol; 2020 Feb; 18(2):116-125. PubMed ID: 32558805
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low temperature plasma: a novel focal therapy for localized prostate cancer?
    Hirst AM; Frame FM; Maitland NJ; O'Connell D
    Biomed Res Int; 2014; 2014():878319. PubMed ID: 24738076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.